Migraine And Headache
Compared with patients not reporting headache, patients with HRH had significantly greater differences in pre- and post-BUN values.
A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.
The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine.
Fremanezumab treatment may be efficacious in reducing the number of monthly headache days in the long-term in people with chronic migraine.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
Few patients were found to take triptan medications to treat acute migraine, and a majority of those who had, discontinued the treatment due to side effects.
Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.
Investigator analyzed the number of scripts and days of therapy in patients with migraine to determine use and frequency of overuse.
Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
DFN-11, a 3 mg subcutaneous sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine.
People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.
Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.
The location of migraine pain may not be associated with psychiatric distress, emergency department visits, or healthcare use.
Mayne Pharma Group announced the availability of Butalbital/Acetaminophen 50mg/300mg Capsules indicated for the relief of the symptom of complex tension headache.
GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.
The investigators sought to evaluate whether early-life traumatic experiences, stressful life events, and alexithymia are associated with chronic migraine and medication overuse headache.
The risk of cochlear disorders, especially tinnitus, is increased among patients with a history of migraine.
The investigators sought to evaluate the efficacy and safety of mindfulness-based stress reduction and mindfulness-based cognitive therapy in the reduction of the symptoms associated with chronic headaches.
Two-thirds of parents report that their child has had a headache not related to a fall or head injury.
White Matter Hyperintensities Demonstrate Specific Spatiotemporal Evolution in Reversible Cerebral Vasoconstriction SyndromeJuly 18, 2018
The characteristics of white matter hyperintensities were assessed to provide information on the underlying mechanisms of these lesions in individuals with reversible cerebral vasoconstriction syndrome.
Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.
Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.
The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.
For patients with episodic migraine, galcanezumab is better than placebo for reducing migraine headache days.
For patients with episodic migraine, fremanezumab is associated with a reduction in the mean number of monthly migraine days.
Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.
The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).
Allergan announced results from the second Phase 3 trial for their novel acute migraine treatment, ubrogepant.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure